Haemangiopericytoma of the thyroid gland in combination with Hashimoto's disease.

Institute of Pathology, Johannes Gutenberg, University of Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany. .
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin (Impact Factor: 2.56). 10/2004; 445(3):315-9. DOI: 10.1007/s00428-004-1066-5
Source: PubMed

ABSTRACT We present a hitherto unique case of haemangiopericytoma (HP) of the thyroid gland in a 15-year-old female patient suffering from Hashimoto's disease for several months. Since angiogenesis has been discussed to play a major role in both diseases, we examined the expression of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Most interestingly, strong expression of PDGFR alpha and beta was found in spindle-shaped tumour cells and tumour vessels in HP, while VEGF and VEGFR type I and -II were negative in these regions. In contrast, VEGF was expressed in the lymphoid infiltrate of Hashimoto's disease. Since PDGFR-beta is commonly expressed in pericytes, we suggest that the strong expression discovered in this study further supports the view that HP is derived from pericytes. The combination of HP and Hashimoto's disease is most probably a coincidental event. However, this case confirms previous reports demonstrating that in patients with Hashimoto's disease different neoplasias can occur.


Available from: Andreas Gaumann, Jun 15, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oncogenic osteomalacia is a rare metabolic bone disease characterized by hypophosphatemia, renal phosphate wasting, suppressed 1,25-dihydroxyvitamin D production, and osteomalacia. A phosphaturic factor secreted by these tumors is responsible for the symptomatology. The main mechanism underlying this disease condition is an over expression of fibroblast growth factor 23 (FGF-23). Complete excision of these tumors facilitates successful reversal of the problem. We report the case of a patient who was crippled and on extensive investigation revealed an oncogenic osteomalacia with tumor focus in right tibia. The tumor was identified as a mesenchymal tumor, i.e. hemangiopericytoma. Tumor excision alleviated patient symptoms with rapid symptomatic and biochemical improvement.
    Fooyin Journal of Health Sciences 08/2010; 2(3):109-112. DOI:10.1016/S1877-8607(11)60008-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS. The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease. Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas. Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.
    Cancer 02/2012; 118(3):770-6. DOI:10.1002/cncr.26334 · 4.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China A patient with a seven-year history of recurrent metastatic hemangiopericytoma (HPC) was admitted. During his treatment, he received surgical resection, radiotherapy, radiofrequency hyperthermia and chemotherapy using combined doxorubicin, dacarbazin, vincristine, ginsenoside Rg3, and recombinant human endostatin. This synergistic method provides an encouraging model for treating HPC.
    06/2012; 9(2):141-143. DOI:10.3969/j.issn.2095-3941.2012.02.012